ES2184293T3 - Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina. - Google Patents

Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina.

Info

Publication number
ES2184293T3
ES2184293T3 ES98931849T ES98931849T ES2184293T3 ES 2184293 T3 ES2184293 T3 ES 2184293T3 ES 98931849 T ES98931849 T ES 98931849T ES 98931849 T ES98931849 T ES 98931849T ES 2184293 T3 ES2184293 T3 ES 2184293T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
benzhydr
cyclodextrine
piperazine
oral route
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98931849T
Other languages
English (en)
Other versions
ES2184293T5 (es
Inventor
Domenico Fanara
Monique Berwaer
Philippe Nolf
Henri Vranckx
Michel Deleers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3890611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2184293(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB SA filed Critical UCB SA
Publication of ES2184293T3 publication Critical patent/ES2184293T3/es
Application granted granted Critical
Publication of ES2184293T5 publication Critical patent/ES2184293T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas para administración oral, que comprenden una sustancia activa que pertenece a la familia de las benzohidrilpiperazinas sustituidas y al menos una ciclodextrina.
ES98931849T 1997-07-03 1998-07-02 Composiciones farmaceuticas administrables por via oral, que comprenden una benzhidrilpiperazina y una ciclodextrina. Expired - Lifetime ES2184293T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9700572A BE1011251A3 (fr) 1997-07-03 1997-07-03 Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
BE9700572 1997-07-03

Publications (2)

Publication Number Publication Date
ES2184293T3 true ES2184293T3 (es) 2003-04-01
ES2184293T5 ES2184293T5 (es) 2006-01-16

Family

ID=3890611

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98931849T Expired - Lifetime ES2184293T5 (es) 1997-07-03 1998-07-02 Composiciones farmaceuticas administrables por via oral, que comprenden una benzhidrilpiperazina y una ciclodextrina.

Country Status (20)

Country Link
US (1) US6455533B1 (es)
EP (1) EP0994710B2 (es)
JP (2) JP2002508773A (es)
KR (1) KR100551510B1 (es)
CN (1) CN1150900C (es)
AT (1) ATE224717T1 (es)
AU (1) AU727140B2 (es)
BE (1) BE1011251A3 (es)
BR (1) BR9810495A (es)
CA (1) CA2294783C (es)
DE (1) DE69808297T3 (es)
DK (1) DK0994710T4 (es)
ES (1) ES2184293T5 (es)
ID (1) ID23806A (es)
IL (1) IL133397A (es)
NZ (1) NZ501820A (es)
PL (1) PL192348B1 (es)
PT (1) PT994710E (es)
RU (1) RU2192863C2 (es)
WO (1) WO1999001133A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
BR0206979A (pt) * 2001-02-05 2004-04-20 Scherer Technologies Inc R P Métodos e composições para reduzir o paladar de agentes farmaceuticamente ativos
EP1467715B1 (en) * 2002-01-15 2010-11-03 Ucb Farchim S.A. Formulations for oral administration of active compounds
CA2481025A1 (en) * 2002-04-04 2003-10-16 Tanya Havlir Palatable chewable tablet
WO2006011051A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
US20070086974A1 (en) * 2005-10-06 2007-04-19 Gawande Rahul S Cetirizine compositions
US20090269393A1 (en) * 2006-06-12 2009-10-29 Jubliant Organosys Limited Chewable Bilayer Tablet Formulation
JP2008143807A (ja) * 2006-12-07 2008-06-26 Sato Pharmaceutical Co Ltd 感冒薬カプセル剤及びその製造方法
DK2178521T3 (da) * 2007-07-11 2014-04-28 Fertin Pharma As Stabilt medicinsk tyggegummi omfattende cyclodextrin-inklusionskompleks
EP2550967A1 (en) * 2007-07-11 2013-01-30 Fertin Pharma A/S Compressed chewing gum tablet comprising taste-masking agent
WO2009054432A1 (ja) * 2007-10-26 2009-04-30 Daiichi Sankyo Company, Limited 口腔内速崩壊性医薬組成物およびその製造方法
US8138192B2 (en) * 2007-10-31 2012-03-20 Genebiology, Inc. Injectable meclizine formulations and methods
WO2009061465A1 (en) 2007-11-06 2009-05-14 Teva Pharmaceutical Industries Ltd. Chewable formulations
CN102143737A (zh) * 2008-09-05 2011-08-03 麦克内尔-Ppc股份有限公司 制备西替利嗪片剂的方法
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
WO2011110939A2 (en) * 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
CN103037839A (zh) * 2010-06-04 2013-04-10 全球药物科技有限公司 含有矫味剂的口服美其敏水性制剂
CN101905027A (zh) * 2010-07-27 2010-12-08 北京华禧联合科技发展有限公司 含米格列奈钙和环糊精的口服药用组合物
PH12013500477A1 (en) 2010-09-13 2018-01-17 Bev Rx Inc Aqueous drug delivery system comprising off-flavor masking agent
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
RU2589833C2 (ru) * 2013-12-12 2016-07-10 Общество С Ограниченной Ответственностью "Фарма Старт" Твердая лекарственная форма препарата седативного и снотворного действия
CN111632023A (zh) * 2014-03-27 2020-09-08 Ucb法奇姆股份有限公司 包含左西替利嗪的药物组合物
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
KR102110304B1 (ko) * 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
JP7703137B2 (ja) * 2020-02-03 2025-07-07 ケンビュー・ブランズ・エルエルシー セチリジンを含む単層チュアブル錠剤
US20230414597A1 (en) 2020-11-18 2023-12-28 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75816C (fi) 1981-02-06 1988-08-08 Ucb Sa Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
JPS60204712A (ja) * 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd 塩酸メクリジンの安定化液状組成物
JPS63243031A (ja) † 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd 胆汁酸の固形製剤
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
JPH08501561A (ja) † 1992-09-24 1996-02-20 セプラコア，インコーポレイテッド （−）セチリジンを用いたアレルギー疾患の治療のための組成物
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
HU217298B (hu) * 1993-12-01 1999-12-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. (Helyettesített amino)-alkil-amino-piridil-metil-tio-benzimidazol- és -imidazo [5,4-b]piridin-származékok, előállításuk és alkalmazásuk, valamint a vegyületeket tartalmazó gyógyászati készítmények
US5866179A (en) 1996-05-03 1999-02-02 Avant-Garde Technologies & Products S.A. Medicated chewing gum and a process for preparation thereof
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
WO2006011051A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form

Also Published As

Publication number Publication date
DK0994710T4 (da) 2005-10-17
AU727140B2 (en) 2000-12-07
KR100551510B1 (ko) 2006-02-13
US6455533B1 (en) 2002-09-24
DE69808297T3 (de) 2006-01-19
WO1999001133A1 (fr) 1999-01-14
EP0994710B2 (fr) 2005-09-21
ID23806A (id) 2000-05-11
NZ501820A (en) 2000-10-27
JP2007091760A (ja) 2007-04-12
DE69808297T2 (de) 2003-04-17
PT994710E (pt) 2003-02-28
DE69808297D1 (de) 2002-10-31
IL133397A (en) 2005-07-25
BR9810495A (pt) 2000-09-12
HK1029060A1 (en) 2001-03-23
RU2192863C2 (ru) 2002-11-20
EP0994710A1 (fr) 2000-04-26
CN1150900C (zh) 2004-05-26
DK0994710T3 (da) 2003-01-20
CA2294783A1 (fr) 1999-01-14
KR20010014398A (ko) 2001-02-26
BE1011251A3 (fr) 1999-06-01
US20020032217A1 (en) 2002-03-14
CN1261799A (zh) 2000-08-02
CA2294783C (fr) 2006-11-14
PL337794A1 (en) 2000-09-11
ATE224717T1 (de) 2002-10-15
PL192348B1 (pl) 2006-10-31
ES2184293T5 (es) 2006-01-16
EP0994710B1 (fr) 2002-09-25
IL133397A0 (en) 2001-04-30
AU8201598A (en) 1999-01-25
JP2002508773A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
PT994710E (pt) Composicoes farmaceuticas administraveis por via oral incluindo uma benzidrilpiperazina e uma ciclodextrina
BR9611802A (pt) Composições farmacêuticas
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
GT199800101A (es) Composicion farmaceutica solida que contiene un derivado de benzofurano.
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
CO5590918A2 (es) Formulaciones
DE60205870D1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
GT199700052A (es) Sales metanosulfonatode5-(2-4-(1,2-benzoisotiazol-3-il)-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-onadihidratadas
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
ES2160145T3 (es) Composicion farmaceutica para la administracion oral de flavonoides.
ES2176296T3 (es) Composiciones farmaceuticas que permiten la liberacion prolongada de trimetacidina despues de la administracion por via oral.
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
DE122006000057I2 (de) Proteinhaltige arzneimittel
DK0930077T3 (da) Cyclodextrinpræparater indeholdende et avermectin- eller milbemycinderivat
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
BR0011845A (pt) Complexo farmacêutico
AR023056A1 (es) Composiciones farmaceuticas basadas en alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh
ES2187136T3 (es) Composicion farmaceutica para la administracion por via nasal de tiocolchicosida.
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
AR022602A1 (es) Composiciones farmaceuticas topicas que contienen drogas antiinflamatorias no-esteroides
ECSP941154A (es) Procedimiento para preparar una composicion farmaceutica a base de ciclosporina